Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Nash, Peter, Kirkham, Bruce, Okada, Masato, Rahman, Proton, Combe, Benard, Burmester, Gerd-Ruediger, Adams, David H, Kerr, Lisa, Lee, Chin, Shuler, Catherine L, Genovese, Mark, Ahmed, Khalid, Alper, JLanguage:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31429-0
Date:
May, 2017
File:
PDF, 706 KB
english, 2017